Business Wire

HOGAN-LOVELLS

Share
Hogan Lovells White Paper Calls for Flexibility as the EU Establishes Its First-ever Regulatory Framework Enabling the Launch of Autonomous Vehicles

Global law firm Hogan Lovells has today shared its recommendations on the future of Europe’s regulatory framework for autonomous vehicles (AVs), as the European Commission takes an important first step in submitting a Draft EU ADS Regulation to all 27 Member States ahead of a Public Consultation in November.

The regulatory framework published in late September 2021 will be used to help shape the future of AVs across the EU and will have far reaching implications on the AV industry in Europe for years to come.

The Draft EU ADS Regulation sets out the type-approval rules for AVs with regard to their automated driving system (ADS) to create a harmonised pathway for (SAE/ISO) “Level 4” or “fully automated” vehicles to be deployed on public roads across Member States – with no human driver. It also establishes aggregate safety metrics that will be used to benchmark performance, and ultimately will be used as a measurement for allowing AV testing and deployment.

The Hogan Lovells White Paper “The Road to Autonomous Vehicles” issued today identifies three key recommendations for a legal framework for AVs, which will guide regulatory developments at an EU and national level. They include:

  1. A broad, holistic and forward-looking approach to type-approval across Europe is important. The regulatory framework needs to be as flexible as possible. At a minimum, the existing system for type-approval should be used as a foundation and should not be undone for AVs/ADSs only.

  2. The assumption of regulatory responsibility and proof of safety concept should be considered as the decisive factor for regulations. Expertise is key when it comes to putting AVs onto public roads in the market and needs to be considered when allocating roles and responsibilities for different economic operators.

  3. Avoiding ambiguities (in particular to the existing regulatory framework), inconsistencies and the use of unclear terms and definitions that may lead to interpretation issues and delay the development and commercialisation of AVs.

The Draft EU ADS Regulation is part of a broader maturation in Europe’s AV regulatory environment. Other promising efforts are currently being made by France, Germany and the Netherlands, although Germany appears to be deviating from current existing broad definitions and a flexible approach applied at the EU level. The White Paper highlights that a harmonised approach across Europe providing adequate flexibility will be key for the long-term success of AVs.

Patrick Ayad, Global Leader of Mobility and Transportation at Hogan Lovells, said:

“This is a key piece of research on the future of Europe’s regulatory framework for autonomous vehicles.”

“We have an exciting opportunity to introduce autonomous vehicles in Europe. Current efforts made within Europe are encouraging and align well with the recommendations that we have made in our White Paper today. We need to take a broader and holistic approach to type approval as this will be even more valuable and beneficial for this purpose. Technological innovations, emerging new mobility solutions, as well as commercial and corporate partnerships changing the industry landscape call for a flexible framework – this needs to apply across Europe and individual Member States to work.”

Key highlights from the White Paper include:

- AV technology and the industry landscape are evolving rapidly. Developing an automated driving system (ADS) remains a highly-resource intensive endeavour, requiring extensive technical and specialised expertise.

- The challenge facing regulators is to provide a legal framework to allow for commercial deployment across Europe. This means setting appropriate “type-approval” requirements that meet the dual purposes of ensuring the technology is safe as well as facilitating commercial deployment in a way that will deliver the value the EU Commission has envisaged.

- Steps taken by the French, German and Dutch Governments are encouraging in that they seek to set out the legal basis for the approval of ISO/SAE Level 4 driving automation directly, and not lower-level human driver-assistance systems.

- The shift from conventional vehicles to AVs is a unique and disruptive scenario: it is the first time that not only the vehicle but also the driver (the ADS) are being regulated and type-approved.

- Innovation calls for flexibility. Regulating innovation calls for the same. An open and flexible approach has proven successful for AV testing over many years, building on - rather than replacing - existing regulatory concepts. This same lesson should be applied when it comes to the key question of defining which entity (or group of entities) should be responsible for presenting the AV - that is, the base vehicle and the ADS - to a regulator for type-approval.

- While the European Commission appears to be effectively addressing this issue under its forthcoming ADS Type Approval Implementing Act (which is expected to be in place by July 2022), it seems that the German Government takes a different approach under its current draft for an ordinance implementing the newly adopted changes to road traffic laws enabling regular operation of SAE/ISO Level 4 AVs, which, contrary to existing laws, introduces a new definition for “manufacturer” that refers to the “vehicle manufacturer”.

Hogan Lovells is one of the world's leading law firms in its dedication to an industry sector focused-approach, enabling us to advise our clients in a sector-focused manner, across practice groups, borders and industries.

In 2020, we created a new global Mobility and Transportation sector group, bringing together our already established industry sectors Automotive (and Mobility) and Aerospace and Defence as well as our new industry sector Transport and Logistics, to better represent the rapid changes facing the Mobility and Transportation world.

The full White Paper can be accessed here .

[Ends]

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands12.1.2026 13:30:00 CET | Press release

Cellares’ new IDMO Smart Factory in Leiden, Netherlands, expands commercial-scale manufacturing capacity for European cell therapy patient populations through a standardized, automated, and highly scalable facility model Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important as programs advance from clinical development toward commercial supply. The new Netherlands hub is designed to provide European drug developers with access to automated manufacturing infrastructure, while maintaining alignment to a common production stan

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas12.1.2026 13:30:00 CET | Press release

Updated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework. The updated protocol expands France’s previously granted AAC authorization for BOT+BAL in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases to eligible patients with certain ovarian cancers and soft-tissue sarcomas—diseases with substantial unmet medical need after standard options have been exhausted. The revised protocol is designed to broaden the eligibility criteria, allowing more patients with advanced solid tumors to have early access to BOT+BAL under reimbursed compassionate

Lilac and Traxys Announce Binding 10-Year Offtake Agreement for Great Salt Lake Lithium Production12.1.2026 13:00:00 CET | Press release

Definitive agreement secures 100% of Phase 1 production, advancing project toward final investment decision Lilac Solutions, a leading provider of direct lithium extraction technology, and Traxys North America, a leading global physical trader and merchant in metals and natural resources, today announced a binding 10-year offtake agreement for lithium carbonate produced at Lilac's Great Salt Lake facility in Utah. The agreement represents a major milestone in advancing the project toward construction and establishes a clear commercial pathway for one of the nearest-term domestic lithium projects in the United States. Under the terms of the definitive agreement, Traxys will purchase 50,000 tonnes of lithium carbonate over a 10-year period, representing 100% of the planned Phase 1 production capacity. The agreement is take-or-pay, with agreed pricing mechanisms linked to market indices. The Great Salt Lake Phase 1 facility is designed to produce 5,000 tonnes per annum of battery-grade li

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye